Nucala 100 mg solution for injection in pre-filled pen
Sponsors
Hospices Civils De Lyon, Amsterdam UMC, Glaxosmithkline Research & Development Limited, Amsterdam UMC Stichting
Conditions
AsthmaChronic rhinosinusitis with nasal polyps (CRSwNP)Severe Asthmasevere asthma
Phase 4
Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE
CompletedCTIS2022-501029-19-00
Start: 2022-12-13End: 2025-03-27Target: 130Updated: 2024-01-15
A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma.
Active, not recruitingCTIS2023-509026-21-00
Start: 2024-06-03Target: 170Updated: 2025-12-10
Biomarkers for the prediction of individual CRSwNP patients' responses to mepolizumab
RecruitingCTIS2023-508069-34-01
Start: 2024-08-05Target: 70Updated: 2024-06-03
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
Not yet recruitingCTIS2025-524741-28-00
Target: 142Updated: 2026-06-05